Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension

NCT01033071 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT01033071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01033071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2010
Completion date
November 30, 2010
Enrollment
1,071 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension